Robert W. Baird upgraded shares of Axovant Gene Therapies (NASDAQ:AXGT) from a neutral rating to an outperform rating in a research report released on Monday, BenzingaRatingsTable reports. Robert W. Baird currently has $13.00 price target on the stock, down from their prior price target of $16.00.
AXGT has been the subject of a number of other reports. JMP Securities raised their price objective on shares of Axovant Gene Therapies from $8.00 to $28.00 and gave the stock an outperform rating in a report on Thursday, June 6th. Zacks Investment Research raised shares of Axovant Gene Therapies from a hold rating to a strong-buy rating and set a $5.50 price objective for the company in a report on Friday, June 14th. Cowen reaffirmed a hold rating on shares of Axovant Gene Therapies in a report on Tuesday, July 9th. Leerink Swann started coverage on shares of Axovant Gene Therapies in a report on Friday, June 21st. They set an outperform rating and a $5.79 price objective for the company. Finally, ValuEngine raised shares of Axovant Gene Therapies from a sell rating to a hold rating in a report on Thursday, August 1st. Three analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and an average target price of $26.79.
NASDAQ:AXGT opened at $6.62 on Monday. The stock’s 50-day simple moving average is $6.68. Axovant Gene Therapies has a 52 week low of $3.81 and a 52 week high of $20.80. The company has a quick ratio of 2.63, a current ratio of 1.70 and a debt-to-equity ratio of 0.60.
In other news, CEO Pavan Cheruvu purchased 7,500 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The stock was purchased at an average cost of $5.21 per share, with a total value of $39,075.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 6.60% of the company’s stock.
A number of hedge funds have recently made changes to their positions in AXGT. Tower Research Capital LLC TRC lifted its holdings in Axovant Gene Therapies by 955.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,221 shares of the company’s stock valued at $27,000 after purchasing an additional 3,821 shares during the last quarter. Marshall Wace LLP bought a new position in Axovant Gene Therapies during the 1st quarter valued at about $272,000. Jane Street Group LLC lifted its holdings in Axovant Gene Therapies by 28.8% during the 2nd quarter. Jane Street Group LLC now owns 46,455 shares of the company’s stock valued at $289,000 after purchasing an additional 10,375 shares during the last quarter. Primecap Management Co. CA bought a new position in Axovant Gene Therapies during the 1st quarter valued at about $1,400,000. Finally, BlackRock Inc. bought a new position in Axovant Gene Therapies during the 2nd quarter valued at about $1,482,000.
Axovant Gene Therapies Company Profile
Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.
Featured Story: How Do You Calculate Return on Equity (ROE)?
Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.